Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Auditor change
Director departure
Appointed director
CC transcript
Eterna Therapeutics Inc. (NTN) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/05/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Departure of Directors o...
09/26/2023 8-K/A Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
08/23/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
08/23/2023 EFFECT Form EFFECT - Notice of Effectiveness:
08/14/2023 S-3 Form S-3 - Registration statement under Securities Act of 1933:
08/11/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/10/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Departure of Directors o...
Docs: "Dr. Angel Resignation Letter"
08/02/2023 8-K Investor presentation
Docs: "Eterna Therapeutics Investor Presentation – August 2023"
07/26/2023 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
07/26/2023 D Form D - Notice of Exempt Offering of Securities:
07/26/2023 D Form D - Notice of Exempt Offering of Securities:
07/18/2023 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Securities Purchase Agreement, by and among Eterna Therapeutics Inc. and the purchasers party thereto",
"Form of Senior Convertible Note",
"Form of Common Stock Purchase Warrant",
"Registration Rights Agreement, by and among Eterna Therapeutics Inc. and the purchasers party thereto"
07/13/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "First Amendment to Exclusive License Agreement, by and between Eterna Therapeutics Inc. and Factor Bioscience Limited"
07/11/2023 8-K Quarterly results
05/11/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/05/2023 ARS Form ARS - Annual Report to Security Holders:
05/05/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
05/05/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
05/05/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "RE: Separation Agreement and General Release"
05/02/2023 8-K Quarterly results
04/25/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
04/25/2023 EFFECT Form EFFECT - Notice of Effectiveness:
04/20/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
04/14/2023 S-1 Form S-1 - General form for registration of securities under the Securities Act of 1933:
04/04/2023 SC 13G/A Freebird Partners LP reports a 12.6% stake in Eterna Therapeutics Inc.
03/21/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
03/21/2023 EFFECT Form EFFECT - Notice of Effectiveness:
03/20/2023 8-K Quarterly results
03/20/2023 POS AM Form POS AM - Post-Effective amendments for registration statement:
03/20/2023 10-K Annual Report for the period ended December 31, 2022
02/22/2023 8-K Quarterly results
01/31/2023 SC 13G/A HALPERN JOHN D reports a 8.8% stake in Eterna Therapeutics Inc.
01/26/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
01/10/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy